Encepur Tick-Borne Encephalitis Vaccine Clinical Trials, Dosage, Safety 

Encepur® is a whole virus vaccine containing an inactivated and purified Tick-Borne Encephalitis (TBE) virus/strain prevalent in Central, Eastern, and Northern Europe. The World Health Organization (WHO) recommends vaccination to all age groups, including children, in areas where the disease is highly endemic. For children aged >1 year (ENCEPUR CHILDREN, 0.25 mL) and for Adults and children aged > 12 years (ENCEPUR ADULTS, 0.5 mL).

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.

Encepur Vaccine Indication

Encepur is indicated for actively immunizing high-risk populations against TBE. The WHO says immunization offers the most effective protection and recommends vaccinating all age groups, including children, in areas where the disease is highly endemic.

Encepur Vaccine Dosage

Encepur is administered as an intramuscular injection. Its unique dosing flexibility is supported by proven efficacy and long-term persistence data. ENCEPUR’s rapid schedule: immunisation completed in just 21 days.

Encepur Vaccine Booster

ENCEPUR booster offers protection for those at continued risk of TBE and is recommended every 5 years for those aged 1-49 and every 3 years for those >49.

Encepur Vaccine Availability

As of May 2025, Encepur is marketed in European countries only, with Germany being the largest market.

Encepur Vaccine Revenue

As of May 9, 2025, revenue from sales of Encepur in the first quarter increased to DKK 204 million (DKK 126 million), an increase of 62% compared to the prior year. Strong market growth, increased market shares, and, to some extent, increased stocking by German wholesalers drove the increase. The German market grew by 17% in Q1 versus the prior year, and Encepur's market share was 29%, nearly 2 pp higher than the prior-year level.

Encepur Vaccine News

May 9, 2025 - Bavarian Nordic A/S reported its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million.

October 21, 2019 - Bavarian Nordic announced that it has entered an agreement with GlaxoSmithKline to acquire the manufacturing and global rights to Encepur®.

Encepur Vaccine Clinical Trials

Clinical Trial NCT03294135: This Study aims to investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine

• The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after the first booster with the Tick-Borne Encephalitis (TBE) vaccine.
• This study will further investigate the booster response in subjects who will receive their second booster dose* in this study.

* Any booster given in this study will be the second booster the subject has received (about the follow-up of the previous study).